America has spent decades treating drugs mainly as a law enforcement problem, and the costs show up everywhere: crowded courtrooms, full prisons, stretched police budgets, and treatment systems that many people struggle to enter. Yet addiction, overdose deaths, and illicit supply have not gone away. That gap between effort and results is why drug policy reform has moved from the margins to the center of public debate. The question is no longer whether the old approach deserves scrutiny, but what could replace it. Here are five reforms that could anchor modern drug policy, along with the trade-offs each one carries.

Reform One: Put Public Health at the Center of Drug Policy Reform

Substance use disorder is a medical condition, and punishment alone rarely treats a medical condition. A public health approach starts with access to evidence-based treatment, including medications for opioid use disorder. It adds mental health support, prevention and education, and recovery services such as peer support and stable housing. Diversion programs, which steer people toward care instead of a conviction, can help when addiction drives the offense.

No single model fits everyone, though. A person struggling with stimulants needs different support than someone dependent on opioids, and rural communities often lack clinics altogether. Treatment capacity matters as much as treatment policy. A Portland State University evaluation of Oregon’s recent experiment pointed to implementation gaps and urged policymakers to prioritize links to treatment. Commitment to care is the foundation of modern drug policy, but only if services exist when someone asks for help.

Reform Two: Reconsider Criminal Penalties for Personal Possession

Prosecuting simple possession consumes police time, court capacity, and jail space. A conviction can also follow a person into job applications, rental screenings, and custody disputes. Decriminalization removes or reduces criminal penalties for personal possession. It is not legalization: selling, manufacturing, and trafficking stay illegal, and the supply stays unregulated.

Oregon’s Measure 110 is the best-known American test, and it shows why details matter. It took effect in February 2021 and was reversed by House Bill 4002 in March 2024, which made possession a misdemeanor again while letting defendants avoid jail by entering treatment. Evidence on its effects is contested. A 2023 JAMA Psychiatry study found that the measure did not lead to more deadly overdoses, while a Journal of Health Economics study estimated an increase in overdose deaths. Fentanyl’s arrival muddies every comparison, and most of the cannabis tax money meant for treatment and harm reduction arrived late in the study period. Public patience also ran out: a poll of 1,000 Oregonians found 56% preferred repeal.

The lesson is not that decriminalization fails or succeeds on its own. Serious drug policy reform pairs reduced penalties with funded services, clear public-use rules, and pathways into care. Another point of modern drug policy worth stressing: decriminalization does not end trafficking or erase substance-related harm.

Reform Three: Build Carefully Regulated Legal Markets

Prohibition leaves the supply to criminal organizations that offer no quality control, no labels, and no age checks. A regulated market changes that arrangement. It could include product testing, potency standards, accurate labeling, age limits, licensing and inspections, consumer protections, marketing restrictions, and taxes directed to treatment and prevention. Some risks of unregulated supply, such as unknown strength and contamination, could shrink under that structure. That is why regulation sits at the ambitious end of drug policy reform.

The risks of regulation are just as real. A 2026 Lancet Psychiatry review found that commercialized legal cannabis markets in North America were associated with more use, more cannabis use disorder, and more hospital admissions for psychosis, while there was little evidence that decriminalization raised use or psychiatric disorders. Causation remains hard to establish, but the warning is clear: for-profit incentives push toward cheaper, stronger products. Design therefore matters, through potency limits, advertising bans, and caps on retail density. Nor should every substance be treated alike. Cannabis, psychedelics, stimulants, and opioids carry different risks, and a sensible framework would scale controls to match.

Mark Greer’s book, Freedom: A Rational Alternative to Our Current Failed Drug Policies, adds a perspective here. Rather than offering abstract commentary, it is scenario-driven. It imagines a fictional bill, the “Restoration of Freedom and American Values Act,” that repeals federal drug prohibition and replaces it with regulated, taxed, pharmaceutical-grade distribution, then explores the economic, legal, and societal changes that could follow. The bill exists only inside the book and is not law, and its outcomes are hypothetical, not research findings. Even so, it contributes to the wider conversation by asking readers to picture what a regulated alternative could involve, and that is a useful companion to the research above. Treating regulation as a design problem, not a slogan, defines modern drug policy at its best.

Reform Four: Redirect Enforcement Spending Toward Measurable Results

Federal figures complicate the usual story. In fiscal year 2023, enacted federal drug control spending totaled about $43.7 billion, including roughly $21.6 billion for treatment, $2.7 billion for prevention, $11.4 billion for domestic law enforcement, and $6.9 billion for interdiction. Federal numbers leave out state and local spending on policing, courts, and jails, so the full picture is larger.

Counting dollars is not the same as measuring results. The better question is what each dollar achieves. Funds could support community services, drug market monitoring, public health research, and targeted action against violent trafficking. Not every enforcement dollar can move to clinics, since officers, judges, and correctional staff are not interchangeable with clinicians. Still, agencies could report overdose deaths, treatment retention, and time to care instead of arrests and seizures. Outcome-based budgeting is central to modern drug policy, and to any credible drug policy reform agenda.

Reform Five: Create a Responsible Transition Away From Federal Prohibition

Laws do not implement themselves. Moving away from federal prohibition would require coordination between federal and state law, since state systems already differ, and regulators are able to license, inspect, and enforce. It would also mean confronting the past through review of existing drug convictions, with expungement or resentencing where appropriate. Public education, independent evaluation, transparent reporting, and firm safeguards against access by minors belong in the design from the start.

Oregon again offers a caution. The Portland State evaluation noted that counties need flexibility but must be held accountable for the services they provide. Legislation alone is not enough. Successful drug policy reform needs institutions that implement, monitor, and improve new rules, and modern drug policy needs the humility to change course when evidence demands it.

Conclusion: Drug Policy Reform Is a Long Project, Not a Single Law

Taken together, the five reforms describe one coherent vision: treat addiction as a health issue, narrow the role of criminal penalties, regulate supply where regulation can work, spend by results, and build institutions that can carry the change. Ending the traditional War on Drugs takes more than repealing individual statutes. It means rethinking how society balances public health, individual freedom, public safety, regulation, and criminal justice, with careful implementation, transparent oversight, and continued evaluation. That discipline is the heart of modern drug policy. Readers curious about how a full repeal might unfold can explore Greer’s Freedom as one imagined version of that future. A war implies a victory that never arrives. A policy can be measured, corrected, and improved, which is the kind of progress prohibition has rarely allowed.

Why This Matters: Drug laws shape who is arrested, who receives treatment, what products people consume, and how public money is spent. Because those choices touch public health, liberty, community safety, and the justice system, informed discussion matters more than slogans, and it anchors modern drug policy debates. The research cited here is mixed in places, so this article separates documented findings from opinion and from hypothetical scenarios like the one in Greer’s book. Sound drug policy reform begins with that kind of honesty.